To access the live call by phone, dial 719-457-2627; the conference ID
is 4132697. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media